There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Caribou Biosciences (CRBU – Research Report), Lineage Therap (LCTX – Research Report) and Genelux Corp. (GNLX – Research Report) with bullish sentiments.
Caribou Biosciences (CRBU)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Caribou Biosciences, with a price target of $24.00. The company’s shares closed last Thursday at $3.65, close to its 52-week low of $3.44.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of
Caribou Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $20.00, a 471.4% upside from current levels. In a report issued on May 7, RBC Capital also maintained a Buy rating on the stock with a $19.00 price target.
See today’s best-performing stocks on TipRanks >>
Lineage Therap (LCTX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lineage Therap today and set a price target of $7.00. The company’s shares closed last Thursday at $1.18.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lineage Therap with a $5.25 average price target, representing a 344.9% upside. In a report issued on May 6, Robert W. Baird also maintained a Buy rating on the stock with a $5.00 price target.
Genelux Corp. (GNLX)
In a report released today, Emily Bodnar from H.C. Wainwright initiated coverage with a Buy rating on Genelux Corp. and a price target of $32.00. The company’s shares closed last Thursday at $4.02, close to its 52-week low of $3.06.
According to TipRanks.com, Bodnar is a 3-star analyst with an average return of
Genelux Corp. has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRBU:
- Caribou Biosciences reports Q1 EPS (46c), consensus (41c)
- Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- Caribou Biosciences Advances with FDA Clearance and New Trials
- FDA clears Caribou’s IND application for CB-010 to treat lupus and ERL
